Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G

Abecasis, Ana Barroso; Deforche, Koen; Snoeck, Joke; Bacheler, Lee T; McKenna, Paula; Carvalho, Ana Patrícia; Gomes, Perpétua; Camacho, Ricardo Jorge; Vandamme, Anne-Mieke

AIDS:
doi: 10.1097/01.aids.0000242832.35614.9e
Errata

    The authors would like to apologise for the following error. In the discussion section, the authors refer to a manuscript in preparation. However, the relevant author details were not included. The correct citation is shown below:

    “We have evidence that, at least for resistance to nelfinavir, 89L is the most advantageous amino acid for the virus. When it is the WT, it supports both the 30N and 90M mutational pathways (Grossman et al. manuscript in preparation).”

    Back to Top | Article Outline

    Reference

    Abecasis AB, Deforche K, Snoeck J, Bacheler JT, McKenna P, Carvalho AP, et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005 19: 1799–1806.
    © 2006 Lippincott Williams & Wilkins, Inc.